ZHANG Tony 张彦涛

Tony Zhang, PhD.

  • Co-Founder and CEO, Tyligand Bioscience

Tony Zhang is the cofounder and CEO of Tyligand Bioscience, a clinical stage biotech focusing on the discovery and development of cancer therapeutics to address drug resistance in tumors like NSCLC and TNBC.  Leveraging deep insights into the chemistry of biomolecule phosphorylation, the company has built a differentiated pipeline including 1st-in-class Dual Action Tumor Immune Agonist (DATIA®) assets and a novel platform for ADC payload development. 

Tony has a BS degree in chemistry from Shandong University and a PhD degree from Purdue University. Prior to founding Tyligand, he has served at Eli Lilly for 25 years with escalating responsibilities, including Senior Research Fellow of Small Molecular Design and Development, founding Managing Director of Eli Lilly China R&D; and Vice President of Lilly Global External R&D, Asia. Tony has led multi-disciplined teams in drug discovery and development across several therapeutic areas, and has published more than 60 articles and monographs in the fields of synthetic, medicinal and process chemistry, and pharmaceutical product design. He is the inventor for 30 patents and many commercial manufacturing processes. He has been recognized as a CGP fellow, a Purdue Distinguished Alumnus, and Eli Lilly’s Chairman’s Ovation Awardee.  He has also served as the Chairman of BayHelix 2010-2011.